Daratumumab in multiple myeloma von Nooka, Ajay K., Kaufman, Jonathan L., Hofmeister, Craig C., Joseph, Nisha S., Heffner, Thomas L., Gupta, Vikas A., Sullivan, Harold C., Neish, Andrew S., Dhodapkar, Madhav V., Lonial, Sagar

Volltext

Multiple myeloma immunoglobulin lambda translocations portend poor prognosis von Barwick, Benjamin G., Neri, Paola, Bahlis, Nizar J., Nooka, Ajay K., Dhodapkar, Madhav V., Jaye, David L., Hofmeister, Craig C., Kaufman, Jonathan L., Gupta, Vikas A., Auclair, Daniel, Keats, Jonathan J., Lonial, Sagar, Vertino, Paula M., Boise, Lawrence H.

Volltext

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibody von Benson, Don M., Bakan, Courtney E., Mishra, Anjali, Hofmeister, Craig C., Efebera, Yvonne, Becknell, Brian, Baiocchi, Robert A., Zhang, Jianying, Yu, Jianhua, Smith, Megan K., Greenfield, Carli N., Porcu, Pierluigi, Devine, Steven M., Rotem-Yehudar, Rinat, Lozanski, Gerard, Byrd, John C., Caligiuri, Michael A.

Volltext

Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC von Collins, Shauna M., Bakan, Courtney E., Swartzel, Gina D., Hofmeister, Craig C., Efebera, Yvonne A., Kwon, Hakju, Starling, Gary C., Ciarlariello, David, Bhaskar, Shakthi, Briercheck, Edward L., Hughes, Tiffany, Yu, Jianhua, Rice, Audie, Benson, Don M.

Volltext

PARP1 and POLD2 as prognostic biomarkers for multiple myeloma in autologous stem cell transplant von Thomas, Melissa, Li, Junan, King, Kevan, Persaud, Avinash K, Duah, Ernest, Vangundy, Zachary, Hofmeister, Craig C, Lamba, Jatinder K, Tan, Aik Choon, Fridley, Brooke L, Poi, Ming J, Seligson, Nathan D

Volltext

In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation von Pichiorri, Flavia, Palmieri, Dario, De Luca, Luciana, Consiglio, Jessica, You, Jia, Rocci, Alberto, Talabere, Tiffany, Piovan, Claudia, Lagana, Alessandro, Cascione, Luciano, Guan, Jingwen, Gasparini, Pierluigi, Balatti, Veronica, Nuovo, Gerard, Coppola, Vincenzo, Hofmeister, Craig C, Marcucci, Guido, Byrd, John C, Volinia, Stefano, Shapiro, Charles L, Freitas, Michael A, Croce, Carlo M

Volltext

IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect von Benson, Don M., Bakan, Courtney E., Zhang, Shuhong, Collins, Shauna M., Liang, Jing, Srivastava, Shivani, Hofmeister, Craig C., Efebera, Yvonne, Andre, Pascale, Romagne, Francois, Bléry, Mathieu, Bonnafous, Cécile, Zhang, Jianying, Clever, David, Caligiuri, Michael A., Farag, Sherif S.

Volltext

Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy von Robinson, M Hope, Villa, Nancy Y, Jaye, David L, Nooka, Ajay K, Duffy, Alyssa, McCachren, Samuel S, Manalo, Julia, Switchenko, Jeffrey M, Barnes, Sierra, Potdar, Sayalee, Azeem, Maryam I, Horvat, Ava A, Parihar, Vaunita C, Gong, Jingjing, Liang, Yan, Smith, Geoffrey H, Gupta, Vikas A, Boise, Lawrence H, Kaufman, Jonathan L, Hofmeister, Craig C, Joseph, Nisha S, Lonial, Sagar, Dhodapkar, Kavita M, Dhodapkar, Madhav V

Volltext

MicroRNAs activate natural killer cells through Toll-like receptor signaling von He, Shun, Chu, Jianhong, Wu, Lai-Chu, Mao, Hsiaoyin, Peng, Yong, Alvarez-Breckenridge, Christopher A., Hughes, Tiffany, Wei, Min, Zhang, Jianying, Yuan, Shunzong, Sandhu, Sumeet, Vasu, Sumithira, Benson, Don M., C. Hofmeister, Craig, He, Xiaoming, Ghoshal, Kalpana, Devine, Steven M., Caligiuri, Michael A., Yu, Jianhua

Volltext

Eliminating the monitoring period with subcutaneous daratumumab: a single-center experience von Maples, Kathryn T., Hall, Kevin H., Joseph, Nisha S., Hofmeister, Craig C., Gupta, Vikas, Dhodapkar, Madhav V., Kaufman, Jonathan L., Nooka, Ajay K., Lonial, Sagar

Volltext

Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers von Harshman, Sean W., Canella, Alessandro, Ciarlariello, Paul D., Agarwal, Kitty, Branson, Owen E., Rocci, Alberto, Cordero, Hector, Phelps, Mitch A., Hade, Erinn M., Dubovsky, Jason A., Palumbo, Antonio, Rosko, Ashley, Byrd, John C., Hofmeister, Craig C., Benson, Don M., Paulaitis, Michael E., Freitas, Michael A., Pichiorri, Flavia

Volltext

CYP3A5 influences oral tacrolimus pharmacokinetics and timing of acute kidney injury following allogeneic hematopoietic stem cell transplantation von Seligson, Nathan D, Zhang, Xunjie, Zemanek, Mark C, Johnson, Jasmine A, VanGundy, Zachary, Wang, Danxin, Phelps, Mitch A, Roddy, Julianna, Hofmeister, Craig C, Li, Junan, Poi, Ming J

Volltext

Daratumumab induces CD38 internalization and impairs myeloma cell adhesion von Ghose, Jayeeta, Viola, Domenico, Terrazas, Cesar, Caserta, Enrico, Troadec, Estelle, Khalife, Jihane, Gunes, Emine Gulsen, Sanchez, James, McDonald, Tinisha, Marcucci, Guido, Kaur, Balveen, Rosenzweig, Michael, Keats, Jonathan, Rosen, Steven, Krishnan, Amrita, Satoskar, Abhay R, Hofmeister, Craig C, Pichiorri, Flavia

Volltext

Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience von Scott, Sara A., Marin, Ellen M., Maples, Kathryn T., Joseph, Nisha S., Hofmeister, Craig C., Gupta, Vikas A., Dhodapkar, Madhav V., Kaufman, Jonathan L., Lonial, Sagar, Nooka, Ajay K.

Volltext

Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab... von Joseph, Nisha S., Kaufman, Jonathan L., Gupta, Vilas A., Hofmeister, Craig C., Dhodapkar, Madhav V., Boise, Lawrence H., DiCamillo, Sara M., Roberts, Danielle, Nooka, Ajay K., Lonial, Sagar

Volltext

Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma von Stiff, Andrew, Caserta, Enrico, Sborov, Douglas W, Nuovo, Gerard J, Mo, Xiaokui, Schlotter, Sarah Y, Canella, Alessandro, Smith, Emily, Badway, Joseph, Old, Matthew, Jaime-Ramirez, Alena Cristina, Yan, Pearlly, Benson, Don M, Byrd, John C, Baiocchi, Robert, Kaur, Balveen, Hofmeister, Craig C, Pichiorri, Flavia

Volltext

Phase I Trial of Lenalidomide and CCI-779 in Patients With Relapsed Multiple Myeloma: Evidence for Lenalidomide–CCI-779 Interaction via P-Glycoprotein von HOFMEISTER, Craig C, XIAOXIA YANG, JIA JI, SCHAAF, Larry J, BENSON, Don M, KRAUT, Eric H, HICKS, William J, CHAN, Kenneth K, CHEN, Ching-Shih, FARAG, Sherif S, GREVER, Michael R, BYRD, John C, PICHIORRI, Flavia, PHELPS, Mitch A, PING CHEN, ROZEWSKI, Darlene M, JOHNSON, Amy J, LEE, Seungsoo, ZHONGFA LIU, GARR, Celia L, HADE, Erinn M

Volltext

Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma von Gu, Yanyan, Barwick, Benjamin G., Shanmugam, Mala, Hofmeister, Craig C., Kaufman, Jonathan, Nooka, Ajay, Gupta, Vikas, Dhodapkar, Madhav, Boise, Lawrence H., Lonial, Sagar

Volltext

Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma von Joseph, Nisha S, Kaufman, Jonathan L, Dhodapkar, Madhav V, Hofmeister, Craig C, Almaula, Dhwani K, Heffner, Leonard T, Gupta, Vikas A, Boise, Lawrence H, Lonial, Sagar, Nooka, Ajay K

Volltext

Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial von Jakubowiak, Andrzej J., Griffith, Kent A., Reece, Donna E., Hofmeister, Craig C., Lonial, Sagar, Zimmerman, Todd M., Campagnaro, Erica L., Schlossman, Robert L., Laubach, Jacob P., Raje, Noopur S., Anderson, Tara, Mietzel, Melissa A., Harvey, Colleen K., Wear, Sandra M., Barrickman, Jennifer C., Tendler, Craig L., Esseltine, Dixie-Lee, Kelley, Susan L., Kaminski, Mark S., Anderson, Kenneth C., Richardson, Paul G.

Volltext